ArticleJournal of scleroderma and related disorders2021
Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches.
Article in Journal of scleroderma and related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- The Relationship Between Microbiota, Nutrition, and Gastrointestinal Tract Symptoms in Patients with Systemic Sclerosis: A Systematic Review of the Literature.International journal of molecular sciences · 2025Pooled it
- Gastrointestinal involvement in very early and established systemic sclerosis: insights from the SPRING-SIR national Italian registry.Rheumatology (Oxford, England) · 2026Article
- Eradication of Small Intestinal Bacterial Overgrowth in Systemic Sclerosis: Current Treatment and Perspectives-A Narrative Review.Biomedicines · 2025Review
- Article
- Article
- Association of nutritional status indices with gastrointestinal symptoms in systemic sclerosis: a cross-sectional study.Rheumatology international · 2025Article
- Safety and long-term efficacy of autologous hematopoietic cell transplantation for patients with systemic sclerosis.Frontiers in medicine · 2025Article
- Prevalence and Outcomes of Gastrointestinal Manifestations in an Australian Scleroderma Cohort.Arthritis care & research · 2024Article
- Treatable Traits in Systemic Sclerosis.Clinical reviews in allergy & immunology · 2023Review
- Effects of faecal microbiota transplantation on the small intestinal mucosa in systemic sclerosis.Rheumatology (Oxford, England) · 2023Article
- Particularly severe form of refractory gastrointestinal involvement in systemic sclerosis.BMJ case reports · 2023Article
- Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management.Nature reviews. Rheumatology · 2023Review
- Gastrointestinal symptom severity and progression in systemic sclerosis.Rheumatology (Oxford, England) · 2022Article
- Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis.Journal of scleroderma and related disorders · 2022Article
- Diet in Scleroderma: Is There a Need for Intervention?Diagnostics (Basel, Switzerland) · 2021Article
- Article
- OralMicroorganisms · 2021Article
- The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease.Respiratory research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of research studies in systemic sclerosis focus largely on addressing skin and cardiopulmonary manifestations. Fewer studies assess the pathogenesis and treatment of gastrointestinal tract involvement in systemic sclerosis, despite the fact that the majority of patients with systemic sclerosis have gastrointestinal manifestations and these manifestations are a leading cause of death in systemic sclerosis. The present review provides a comprehensive update on morbidity and mortality outcomes related to gastrointestinal involvement in systemic sclerosis. This review also describes conventional and emerging approaches to managing gastrointestinal symptoms in systemic sclerosis. Recent developments in systemic sclerosis-gastrointestinal research efforts have revealed promising treatment targets, including specific auto-antibodies and microbiota alterations. This review will conclude with an overview of future research directions that may improve our understanding of systemic sclerosis-gastrointestinal involvement and ultimately help to alleviate suffering from this devastating dimension of systemic sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.